Letters to the Editor
Drug Combo Adds No Benefit in Patients with Type 2 Diabetes
Am Fam Physician. 2016 Mar 15;93(6):436-438.
Article: Management of Blood Glucose with Noninsulin Therapies in Type 2 Diabetes
Issue Date: July 1, 2015
See additional reader comments at: http://www.aafp.org/afp/2015/0701/p27.html
to the editor: I applaud the authors for focusing their review on clinically relevant and useful guidance for managing blood glucose levels with noninsulin therapies. The streamlined algorithm in Figure 1, however, is misleading in two regards.
First, the algorithm suggests that a dipeptidyl-peptidase-4 (DPP-4) inhibitor and a glucagon-like peptide-1 (GLP-1) receptor agonist are a recommended combination. Combining medications from these two classes has been investigated in one animal study and one randomized controlled trial in humans.1 In the animal study, adding sitagliptin (Januvia) to liraglutide (Victoza) did not increase the blood concentration of liraglutide, change its pharmacokinetics, or reduce its breakdown. In the human trial, patients taking metformin plus sitagliptin were randomized to either add exenatide (Byetta, Bydureon) or substitute sitagliptin with exenatide. Although the triple-therapy group had an additional 0.3% decrease in A1C level, this change is smaller than what would be expected after adding other recommended agents. Also, it is much lower than the average A1C decrease with GLP-1 receptor agonists (0.8% to 2%) that would be expected in the absence of coadministered DPP-4 inhibitors.
The best available evidence suggests that coadministration of DPP-4 inhibitors and GLP-1 receptor agonists is clinically inferior to other options for enhancing glycemic control. As this review points out, this combination is not approved by the U.S. Food and Drug Administration, nor recommended in the algorithm from the American Diabetes Association (ADA), which is a source for the simplified algorithm in Figure 1.2
Second, Figure 1 suggests that adding a sulfonylurea to a basal insulin is a recommended combination. However, the ADA algorithm does not recommend this combination. In the algorithm's initial publication, the authors noted, “Insulin secretagogues do not seem to provide for additional HbA1c reduction or prevention of hypoglycemia or weight gain after insulin is started, especially after the dose is titrated and stabilized.”3 The American Association of Clinical Endocrinologists/American College of Endocrinology comprehensive diabetes management algorithm from 2015 similarly states, “Consider discontinuing or reducing sulfonylurea after basal insulin started.” 4
Given the variety of recommended combinations to help patients with type 2 diabetes mellitus achieve their personalized goals, we should not be using nonrecommended combinations that add little or no clinical benefit.
Author disclosure: No relevant financial affiliations.
REFERENCESshow all references
1. PL detail-document. Combining a GLP-1 agonist and a DPP-4 inhibitor for type 2 diabetes. Pharmacist's Letter/Prescriber's Letter. August 2012....
2. American Diabetes Association. Standards of medical care in diabetes—2016. Approaches to glycemic treatment. Diabetes Care. 2016;39(suppl 1):S54.
3. Inzucchi SE, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears in Diabetologia. 2013;56(3):680]. Diabetologia. 2012;55(6):1577–1596.
4. Garber AJ, et al. AACE/ACE comprehensive diabetes management algorithm. 2015. Endocr Pract. 2015;21(4):438–447.
in reply: We thank Dr. Geurin for bringing up two issues that may have caused confusion. The intent of the algorithm was to simplify the available medication choices, rather than recommend specific medications or combinations as preferred add-on therapy. We recommended that a comprehensive, patient-centered approach be used to select drug therapy, while considering A1C levels, fasting or postprandial glucose control, weight loss, and adverse effects. We thought the similar mechanisms of action for drug classes listed in eTable B would lead readers to conclude that concomitant therapy would not be acceptable, but we should have been more explicit.
Dr. Geurin's second concern was that Figure 1 also suggested that the addition of a sulfonylurea to established basal insulin therapy was a recommended combination. Although we concur that this drug combination is not ideal, we also recognize that some patients may have limited medication choices because of cost, adverse effects, contraindications, or personal preference. An exhaustive review of the evidence for and against various combination therapies was beyond the scope of our article.
Author disclosure: No relevant financial affiliations.
Send letters to firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.
Copyright © 2016 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions